Gauci, Marie-Léa Boudou, Philippe Baroudjian, Barouyr Vidal-Trecan, Tiphaine Da Meda, Laetitia Madelaine-Chambrin, Isabelle Basset-Seguin, Nicole Bagot, Martine Pages, Cécile Mourah, Samia
...
Published in
Cancer Immunology Immunotherapy
Anti-PD-1 and anti-CTLA-4 antibodies cause immune-related side effects such as autoimmune type 1 diabetes (T1D). It has also been suggested that by increasing TNF-α, IL-2 and IFN-γ production, anti-PD-1 and/or anti-CTLA-4 treatment could affect pancreatic beta cell function and insulin sensitivity. This study was based on a retrospective observatio...
Sckisel, Gail D. Mirsoian, Annie Bouchlaka, Myriam N. Tietze, Julia K. Chen, Mingyi Blazar, Bruce R. Murphy, William J.
Published in
Cancer Immunology, Immunotherapy
We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of...
Ames, Erik Murphy, William J.
Published in
Cancer Immunology, Immunotherapy
The past decade has witnessed a burgeoning of research and further insight into the biology and clinical applications of natural killer (NK) cells. Once thought to be simple innate cells important only as cytotoxic effector cells, our understanding of NK cells has grown to include memory-like responses, the guidance of adaptive responses, tissue re...
Vik-Mo, Einar Osland Nyakas, Marta Mikkelsen, Birthe Viftrup Moe, Morten Carstens Due-Tønnesen, Paulina Suso, Else Marit Inderberg Sæbøe-Larssen, Stein Sandberg, Cecilie Brinchmann, Jan E. Helseth, Eirik
...
Published in
Cancer Immunology, Immunotherapy
BackgroundThe growth and recurrence of several cancers appear to be driven by a population of cancer stem cells (CSCs). Glioblastoma, the most common primary brain tumor, is invariably fatal, with a median survival of approximately 1 year. Although experimental data have suggested the importance of CSCs, few data exist regarding the potential relev...
Mandl, Stefanie J. Rountree, Ryan B. Dalpozzo, Katie Do, Lisa Lombardo, John R. Schoonmaker, Peter L. Dirmeier, Ulrike Steigerwald, Robin Giffon, Thierry Laus, Reiner
...
Published in
Cancer Immunology, Immunotherapy
MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occurred despite a strong tumor-mediated immunosuppressive environ...
Bouwhuis, Marna G. Gast, Andreas Figl, Adina Eggermont, Alexander M. M. Hemminki, Kari Schadendorf, Dirk Kumar, Rajiv
Published in
Cancer Immunology, Immunotherapy
The appearance of vitiligo and spontaneous regression of the primary lesion in melanoma patients illustrate a relationship between tumor immunity and autoimmunity. T lymphocytes play a major role both in tumor immunity and autoimmunity. CD28, Cytotoxic T lymphocyte antigen 4 (CTLA4) and inducible costimulator (ICOS) molecules are important secondar...
Andersen, Mads Hald Sørensen, Rikke Bæk Schrama, David Svane, Inge Marie Becker, Jürgen C. thor Straten, Per
Published in
Cancer Immunology, Immunotherapy
Harnessing of the immune system by the development of ‘therapeutic’ vaccines, for the battle against cancer has been the focus of tremendous research efforts over the past two decades. As an illustration of the impressive amounts of data gathered over the past years, numerous antigens expressed on the surface of cancer cells, have been characterize...
Frederiksen, Klaus Stensgaard Lundsgaard, Dorthe Freeman, Jeremy A. Hughes, Steven D. Holm, Thomas L. Skrumsager, Birte K. Petri, Andreas Hansen, Lasse T. McArthur, Grant A. Davis, Ian D.
...
Published in
Cancer Immunology, Immunotherapy
PurposeHuman interleukin-21 (IL-21) is a class I cytokine previously reported in clinical studies on immune responsive cancers. Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine.Experimental designRecombinant IL-21 was administered by intravenous bolus injection at dose levels f...
